These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28748724)

  • 1. Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.
    Filippatos T; Tzavella E; Rizos C; Elisaf M; Liamis G
    Expert Opin Drug Saf; 2017 Oct; 16(10):1121-1132. PubMed ID: 28748724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
    Tsimihodimos V; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):399-408. PubMed ID: 27819144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.
    Opie LH
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):331-4. PubMed ID: 24825435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactic acidosis induced by metformin in a chronic hemodialysis patient with diabetes mellitus type 2.
    Altun E; Kaya B; Paydaş S; Sarıakçalı B; Karayaylalı I
    Hemodial Int; 2014 Apr; 18(2):529-31. PubMed ID: 24299454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
    Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
    G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs.
    Miltiadous G; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):267-76. PubMed ID: 14740076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
    Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum electrolyte abnormalities caused by drugs.
    Brater DC
    Prog Drug Res; 1986; 30():9-69. PubMed ID: 3544049
    [No Abstract]   [Full Text] [Related]  

  • 11. Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy.
    Sarafidis PA; Georgianos PI; Lasaridis AN
    Expert Opin Drug Saf; 2010 Mar; 9(2):259-73. PubMed ID: 20095916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone.
    Liao L; Yang M; Qiu LL; Mou YR; Zhao JJ; Dong JJ
    Chin Med J (Engl); 2010 Dec; 123(24):3684-8. PubMed ID: 22166651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin induced lactic acidosis--particularities and course.
    Strugaru AM; Botnariu G; Agoroaei L; Grigoriu IC; Butnaru E
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(4):1035-42. PubMed ID: 24502087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of approved pioglitazone combinations for type 2 diabetes.
    Forst T; Hanefeld M; Pfützner A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1571-84. PubMed ID: 21639813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metformin-associated lactic acidosis].
    Orban JC; Ghaddab A; Chatti O; Ichai C
    Ann Fr Anesth Reanim; 2006 Oct; 25(10):1046-52. PubMed ID: 17005358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone/metformin (Actoplus met).
    Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.